Filing Details
- Accession Number:
- 0001645627-18-000080
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-20 11:50:23
- Reporting Period:
- 2018-12-14
- Accepted Time:
- 2018-12-20 11:50:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528172 | Endonovo Therapeutics Inc. | ENDV | Pharmaceutical Preparations (2834) | 452552528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1645627 | Scott Michael Mann | 6320 Canoga Avenue Woodland Hills CA 91367 | President | No | Yes | No | No |
Transaction Summary
Purchased: | 9,000 shares | Avg. Price: $0.02 | Total Value: $195.00 |
Number of Shares After Transactions: | 26,367,898 shares |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-12-14 | 2,000 | $0.02 | 26,360,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-17 | 1,000 | $0.02 | 26,361,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-17 | 1,000 | $0.02 | 26,362,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-17 | 1,000 | $0.02 | 26,363,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-19 | 1,000 | $0.02 | 26,364,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-19 | 1,000 | $0.02 | 26,365,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-20 | 1,000 | $0.02 | 26,366,898 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-12-20 | 1,000 | $0.02 | 26,367,898 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |